Q&A with Dr. Matt Kaeberlein, World-Renowned Longevity Expert and CEO of Optispan.
Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan and host of the Optispan Podcast. He is also an Affiliate Professor of Oral Health Sciences at the University of Washington and a Co-Founder of both the Dog Aging Project and the non-profit 501c3 Dog Aging Institute. He has also co-founded two companies: Ora Biomedical, a longevity drug discovery biotech and Optispan, Inc. a leading clinical healthcare technology company. Dr. Kaeberlein is deeply committed to advancing human and animal health by developing new technologies for health optimization and targeting the biological processes underlying aging and age-related disease.
In a recent article published by CityBiz, our CEO Matt Kaeberlein answered several questions:
You’ve spent decades studying the biology of aging—what made you decide to move from academia into the clinical side of longevity with the launch of Optispan?
Optispan positions itself as a science-first longevity platform. How do you ensure the interventions you offer are backed by the most rigorous and up-to-date aging research?
One of the biggest challenges in longevity care is distinguishing hype from evidence. What biomarkers or diagnostics do you believe are most predictive of biological aging, and how are they integrated into Optispan’s approach?
There’s growing debate about whether longevity interventions should be targeted at the general population or the already health-optimized. Who is the ideal patient for Optispan—and how do you balance personalization with scalability?
You’ve previously expressed both enthusiasm and caution around drugs like rapamycin. How does Optispan approach pharmaceutical interventions for aging—and where do you draw the line on what’s clinically appropriate versus still too experimental?
The longevity field is exploding with innovation. What are some new or emerging tools, therapies, or diagnostics you’re most excited about that Optispan may integrate in the future?
Ultimately, how do you define success for Optispan—not just in terms of business growth, but in actually moving the needle on healthy lifespan for your patients?
If you’re interested in reading the answers to these questions, click here to read the article!
